Viaskin Milk 150 mcg + Viaskin Milk 300 mcg + Viaskin Milk 500 mcg + Viaskin Placebo

Phase 1/2Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Food Allergy

Conditions

Food Allergy

Trial Timeline

Nov 1, 2014 → Dec 22, 2020

NCT ID

NCT02223182

About Viaskin Milk 150 mcg + Viaskin Milk 300 mcg + Viaskin Milk 500 mcg + Viaskin Placebo

Viaskin Milk 150 mcg + Viaskin Milk 300 mcg + Viaskin Milk 500 mcg + Viaskin Placebo is a phase 1/2 stage product being developed by DBV Technologies for Food Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT02223182. Target conditions include Food Allergy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02223182	Phase 1/2	Completed	Nov 1, 2014	Dec 22, 2020	Food Allergy

Competing Products

17 competing products in Food Allergy

See all competitors

Product	Company	Stage	Hype Score
Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment C	Daiichi Sankyo	Phase 1	33
E7386	Eisai	Phase 1	33
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solution	AstraZeneca	Phase 1	33
Acalabrutinib	AstraZeneca	Phase 2	52
esomeprazole/ASA Fixed Dose Combination (FDC)	AstraZeneca	Phase 1	33
Ligelizumab 120 mg + Ligelizumab 240 mg	Novartis	Phase 3	77
Omalizumab	Novartis	Approved	85
Omalizumab Injection	Roche	Approved	85
Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) + Placebo for GLA + Placebo for SLIT PE	Sanofi	Phase 1	32
Dupilumab	Regeneron Pharmaceuticals	Pre-clinical	22
linvoseltamab + dupilumab	Regeneron Pharmaceuticals	Phase 1	32
Dupilumab	Regeneron Pharmaceuticals	Phase 2	51
Sativex + Sativex + Sativex + Sativex	Jazz Pharmaceuticals	Phase 1	30
fruquintinib	HUTCHMED	Phase 1	28
Volitinib	HUTCHMED	Phase 1	28
AZD1722 salt tablet + AZD1722 free base tablet + AZD1722 free base tablet + Omeprazole	Ardelyx	Phase 1	28
E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3	Allergy Therapeutics	Phase 1	28

Other Products from DBV Technologies

Viaskin Peanut 250 mcg + PlaceboPhase 3

DBV712 250 mcgPhase 3

DBV712 + DBV712Phase 3

Part A Viaskin Peanut 250 mcg + Part A Viaskin Peanut 100 mcg + Part A Placebo + Part B Viaskin Peanut 250 mcg + Part B PlaceboPhase 3

Viaskin Peanut 250mcg + PlaceboPhase 3